Showing posts with label Retinopathy of Prematurity. Show all posts
Showing posts with label Retinopathy of Prematurity. Show all posts

Thursday, August 20, 2015

Amniotic membrane derived stem cell transplants show benefit in retinal diseases

(c) Cell Transplantation
A team of researchers at the CHA University in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy, which is used to simulate many retinal diseases. The treatment aimed at suppressing abnormal angiogenesis (blood vessel growth) which is recognized as the cause of many eye diseases, such as diabetic retinopathy and age-related macular degeneration. The researchers reported that the AMSCs successfully migrated to the retinas of the test animals and, because of the growth factors secreted by the cells, were able to suppress retinal neovascularization.

Wednesday, July 15, 2015

Intravitreal bevacizumab appears to be safe in treatment of retinopathy of prematurity


The use of intravitreal bevacizumab appears to be safe in preterm infants for treatment of retinopathy of prematurity, according to a long-term multicenter study.

Friday, January 23, 2015

Telemedicine in premature babies with ROP

Retinopathy of prematurity (ROP) continues to be an ongoing challenge for both ophthalmologists and neonatologists and remains a significant threat to vision for extremely premature infants despite the availability of therapeutic modalities. It remains a leading cause of morbidity despite, (and interestingly) as well as because of, advances in neonatal care, which have improved survival rates of at-risk infants born prematurely. Many controlled clinical trials have shown that application of therapies at the appropriate time is essential to successful outcomes in premature infants affected by ROP.